research (1)

Temelimab: Early clinical trial suggests potential for remyelination

November 2, 2021 | Southmedia

An update about the latest MS research

Results from an early-stage clinical trial suggest that temelimab may promote remyelination and prevent loss of nerve cells.

Information from the MS Trust website: 

The study in brief

Current disease modifying drugs can reduce damage to myelin but can’t stop it completely or repair damage that has already happened. Laboratory studies have indicated that a potential new treatment, temelimab, could promote remyelination. Its potential in people with MS has been assessed in an early clinical trial.

270 people with relapsing remitting MS were recruited. They took one of three doses of temelimab or placebo, given as an intravenous infusion every four weeks. After 24 weeks, people in the placebo group switched to one of the three temelimab doses while those who had started on temelimab remained on their original dose. Treatment continued for up to 96 weeks.

At 24 weeks, there was no difference in the number of active lesions between the three doses of temelimab and placebo. At the end of the study, people who had taken the highest dose of temelimab throughout had fewer T1-hypointense lesions. This type of lesion, also known as a black hole, is associated with MS disability and progression. There was also a reduction in brain tissue loss and improvement in MRI markers of remyelination.

These results suggest that temelimab has little effect on the inflammatory MS activity which is responsible for relapses. However, its effect on MRI markers suggest that it may promote remyelination and prevent loss of nerves. Researchers have set up another study to evaluate temelimab further; this study is underway and results are expected in the first half of 2022.”

You can read more on the MS Trust website here:

Scroll to Top
Skip to content